• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Lack of secondary microthrombosis after thrombin‐induced stroke in mice and non‐human primates
ConclusionsOur data demonstrates that secondary microthrombosis does not occur after thrombin‐induced stroke. In view of that, the pathophysiological roles of hematologic players promoting or protecting from secondary microthrombosis (such as Factor XII, von Willebrand Factor, T‐cells…) deserve to be reevaluated in non‐TMVO stroke models.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - December 16, 2013 Category: Hematology Authors: Maxime Gauberti, Sara Martinez Lizarrondo, Cyrille Orset, Denis Vivien Tags: Brief Report ‐ Vascular Biology Source Type: research

Reduced prevalence of arterial thrombosis in von Willebrand disease
ConclusionsThis is the first study showing that VWD patients have a reduced prevalence of arterial thrombosis and provides important insights into the role of VWF in the pathogenesis of arterial thrombosis.© 2013 International Society on Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis - March 18, 2013 Category: Hematology Authors: Y V. Sanders, J Eikenboom, E M. Wee, J G. Bom, M H. Cnossen, M E.L. Degenaar‐Dujardin, K Fijnvandraat, P W. Kamphuisen, B A.P. Laros‐ Gorkom, K Meijer, E P. Mauser‐Bunschoten, F W.G. Leebeek, Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
ConclusionIn total, 11.4% of caplacizumab‐treated patients and 43.2% of placebo‐treated patients experienced one or more major thromboembolic events, experienced an exacerbation, or died. This analysis shows the potential for caplacizumab to reduce the risk of major thromboembolic morbidities and mortality associated with aTTP.
Source: Journal of Thrombosis and Haemostasis - June 5, 2017 Category: Hematology Authors: F. Peyvandi, M. Scully, J. A. Kremer Hovinga, P. Kn öbl, S. Cataland, K. De Beuf, F. Callewaert, H. De Winter, R. K. Zeldin Tags: Brief Report Source Type: research

Plasma ADAMTS13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis
ConclusionLow levels of ADAMTS13 are associated with an increased risk of MI.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 1, 2015 Category: Hematology Authors: A. Maino, B. Siegerink, L. A. Lotta, J. T. B. Crawley, S. le Cessie, F. W. G. Leebeek, D. A. Lane, G. D. O. Lowe, F. Peyvandi, F. R. Rosendaal Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Plasma ADAMTS‐13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis
ConclusionsLow ADAMTS‐13 levels are associated with an increased risk of myocardial infarction.
Source: Journal of Thrombosis and Haemostasis - July 14, 2015 Category: Hematology Authors: A. Maino, B. Siegerink, L. A. Lotta, J. T. B. Crawley, S. Cessie, F. W. G. Leebeek, D. A. Lane, G. D. O. Lowe, F. Peyvandi, F. R. Rosendaal Tags: Original Article Source Type: research

Low ADAMTS ‐13 activity and the risk of coronary heart disease – a prospective cohort study: the Rotterdam Study
ConclusionsLow ADAMTS‐13 activity is associated with an increased risk of coronary heart disease in the elderly, independently of VWF and established cardiovascular risk factors.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - August 24, 2016 Category: Hematology Authors: M.A.H. Sonneveld, M. Kavousi, M.A. Ikram, A. Hofman, O.L. Rueda Ochoa, P.L. Turecek, O.H. Franco, F.W.G. Leebeek, M.P.M. de Maat Tags: Original Article ‐ Cardiovascular Medicine Source Type: research